Alternative transcription and alternative splicing in cancer

Pharmacology and Therapeutics

Volumn 136, Issue 3, 2012, Pages 283-294

  Pal, Sharmistha ^a   Gupta, Ravi ^a   Davuluri, Ramana V ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Alternative splicing; Alternative transcription; Cancer diagnostics; Cancer therapeutics; Protein isoforms; Transcript variants

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 8055; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FICLATUZUMAB; FORETINIB; GEFITINIB; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; NARNATUMAB; OFATUMUMAB; ONARTUZUMAB; PAZOPANIB; PROTEOME; RAPAMYCIN; RIDAFOROLIMUS; RILOTUMUMAB; RITUXIMAB; RUXOLITINIB; SUNITINIB; TIVANTINIB; TOSITUMOMAB; TRANSCRIPTOME; TRASTUZUMAB; TRICIRIBINE PHOSPHATE;

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ALTERNATIVE TRANSCRIPTION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RESISTANCE; DNA METHYLATION; DNA MODIFICATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; INTRON RETENTION; NEOPLASM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

ALTERNATIVE SPLICING; ANIMALS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; PROTEIN ISOFORMS; PROTEOME; TRANSCRIPTOME;

EID: 84867852880     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.08.005     Document Type: Review

References (129)

1. L.O. Albulescu, N. Sabet, M. Gudipati, N. Stepankiw, Z.J. Bergman, and T.C. Huffaker A quantitative, high-throughput reverse genetic screen reveals novel connections between Pre-mRNA splicing and 5′ and 3′ end transcript determinants PLoS Genet 8 2012 e1002530
2. M. Allo, V. Buggiano, J.P. Fededa, E. Petrillo, I. Schor, and M. de la Mata Control of alternative splicing through siRNA-mediated transcriptional gene silencing Nat Struct Mol Biol 16 2009 717 724
3. O. Anczukow, A.Z. Rosenberg, M. Akerman, S. Das, L. Zhan, and R. Karni The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation Nat Struct Mol Biol 19 2012 220 228
4. D. Angeloni, A. Danilkovitch-Miagkova, T. Ivanova, E. Braga, E. Zabarovsky, and M.I. Lerman Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter Oncogene 26 2007 4499 4512
5. C. Bardella, B. Costa, P. Maggiora, S. Patane, M. Olivero, and G.N. Ranzani Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression Cancer Res 64 2004 5154 5161
6. L.O. Barrera, Z. Li, A.D. Smith, K.C. Arden, W.K. Cavenee, and M.Q. Zhang Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs Genome Res 18 2008 46 59
7. D.O. Bates, T.G. Cui, J.M. Doughty, M. Winkler, M. Sugiono, and J.D. Shields VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 2002 4123 4131
8. A. Bemmo, C. Dias, A.A. Rose, C. Russo, P. Siegel, and J. Majewski Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities PLoS One 5 2010 e11981
9. J.N. Boeckel, V. Guarani, M. Koyanagi, T. Roexe, A. Lengeling, and R.T. Schermuly Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1 Proc Natl Acad Sci U S A 108 2011 3276 3281
10. R. Boidot, F. Vegran, and S. Lizard-Nacol Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy Int J Mol Med 23 2009 285 291
11. J.P. Brunet, P. Tamayo, T.R. Golub, and J.P. Mesirov Metagenes and molecular pattern discovery using matrix factorization Proc Natl Acad Sci U S A 101 2004 4164 4169
12. E. Buratti, and D. Baralle Exon skipping mutations in neurofibromatosis Methods Mol Biol 867 2012 65 76
13. N. Cancer Genome Atlas Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
14. X. Cao, J. Geradts, M.W. Dewhirst, and H.W. Lo Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells Oncogene 31 2012 104 115
15. P. Carninci, A. Sandelin, B. Lenhard, S. Katayama, K. Shimokawa, and J. Ponjavic Genome-wide analysis of mammalian promoter architecture and evolution Nat Genet 38 2006 626 635
16. J. Cheong, Y. Yamada, R. Yamashita, T. Irie, A. Kanai, and H. Wakaguri Diverse DNA methylation statuses at alternative promoters of human genes in various tissues DNA Res 13 2006 155 167
17. S.H. Choi, K. Heo, H.M. Byun, W. An, W. Lu, and A.S. Yang Identification of preferential target sites for human DNA methyltransferases Nucleic Acids Res 39 2011 104 118
18. W.S. Cleveland, E. Grosse, and W.M. Shyu Local Regression Models 1992 Wadsworth & Brooks/Cole
19. C. Collesi, M.M. Santoro, G. Gaudino, and P.M. Comoglio A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype Mol Cell Biol 16 1996 5518 5526
20. P. Cramer, C.G. Pesce, F.E. Baralle, and A.R. Kornblihtt Functional association between promoter structure and transcript alternative splicing Proc Natl Acad Sci U S A 94 1997 11456 11460
21. R. Dammann, T. Takahashi, and G.P. Pfeifer The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas Oncogene 20 2001 3563 3567
22. S. Das, O. Anczukow, M. Akerman, and A.R. Krainer Oncogenic splicing factor Srsf1 is a critical transcriptional target of Myc Cell Rep 1 2012 110 117
23. C.J. David, and J.L. Manley Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged Genes Dev 24 2010 2343 2364
24. R.V. Davuluri, Y. Suzuki, S. Sugano, C. Plass, and T.H. Huang The functional consequences of alternative promoter use in mammalian genomes Trends Genet 24 2008 167 177
25. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 2008 5469 5477
26. A. DiFeo, L. Feld, E. Rodriguez, C. Wang, D.G. Beer, and J.A. Martignetti A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response Cancer Res 68 2008 965 970
27. M. Dutertre, L. Gratadou, E. Dardenne, S. Germann, S. Samaan, and R. Lidereau Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer Cancer Res 70 2010 3760 3770
28. K.L. Fox-Walsh, and K.J. Hertel Splice-site pairing is an intrinsically high fidelity process Proc Natl Acad Sci U S A 106 2009 1766 1771
29. M.A. Friedberg, F.A. Spellman, A.R. Pilkerton, L.E. Perraut Jr., and R.F. Stephens An alternative technique of local anesthesia for vitreoretinal surgery Arch Ophthalmol 109 1991 1615 1616
30. M. Fujitani, G.I. Cancino, C.B. Dugani, I.C. Weaver, A. Gauthier-Fisher, and A. Paquin TAp73 acts via the bHLH Hey2 to promote long-term maintenance of neural precursors Curr Biol 20 2010 2058 2065
31. C. Ghigna, S. Giordano, H. Shen, F. Benvenuto, F. Castiglioni, and P.M. Comoglio Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene Mol Cell 20 2005 881 890
32. S. Gopalakrishnan, B.O. Van Emburgh, J. Shan, Z. Su, C.R. Fields, and J. Vieweg A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding Mol Cancer Res 7 2009 1622 1634
33. Z. Guo, X. Yang, F. Sun, R. Jiang, D.E. Linn, and H. Chen A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
34. R. Gupta, P. Wikramasinghe, A. Bhattacharyya, F.A. Perez, S. Pal, and R.V. Davuluri Annotation of gene promoters by integrative data-mining of ChIP-seq Pol-II enrichment data BMC Bioinformatics 11 Suppl. 1 2010 S65
35. S.R. Hann Methionine deprivation regulates the translation of functionally-distinct c-Myc proteins Adv Exp Med Biol 375 1995 107 116
36. S.J. Harper, and D.O. Bates VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8 2008 880 887
37. C. Henry, M. Deschamps, P.S. Rohrlich, J.R. Pallandre, J.P. Remy-Martin, and M. Callanan Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance Blood 115 2010 2420 2429
38. R.S. Illingworth, U. Gruenewald-Schneider, S. Webb, A.R. Kerr, K.D. James, and D.J. Turner Orphan CpG islands identify numerous conserved promoters in the mammalian genome PLoS Genet 6 2010
39. D.E. Johnson, J. Lu, H. Chen, S. Werner, and L.T. Williams The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain Mol Cell Biol 11 1991 4627 4634
40. A. Kalsotra, and T.A. Cooper Functional consequences of developmentally regulated alternative splicing Nat Rev Genet 12 2011 715 729
41. R. Karni, E. de Stanchina, S.W. Lowe, R. Sinha, D. Mu, and A.R. Krainer The gene encoding the splicing factor SF2/ASF is a proto-oncogene Nat Struct Mol Biol 14 2007 185 193
42. L. Kerosuo, and M. Bronner-Fraser What is bad in cancer is good in the embryo: importance of EMT in neural crest development Semin Cell Dev Biol 23 2012 320 332
43. A.T. Kho, Q. Zhao, Z. Cai, A.J. Butte, J.Y. Kim, and S.L. Pomeroy Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers Genes Dev 18 2004 629 640
44. K. Kimura, A. Wakamatsu, Y. Suzuki, T. Ota, T. Nishikawa, and R. Yamashita Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes Genome Res 16 2006 55 65
45. P. Kolasinska-Zwierz, T. Down, I. Latorre, T. Liu, X.S. Liu, and J. Ahringer Differential chromatin marking of introns and expressed exons by H3K36me3 Nat Genet 41 2009 376 381
46. A.R. Kornblihtt Promoter usage and alternative splicing Curr Opin Cell Biol 17 2005 262 268
47. A.R. Kornblihtt Coupling transcription and alternative splicing Adv Exp Med Biol 623 2007 175 189
48. A. Lapuk, H. Marr, L. Jakkula, H. Pedro, S. Bhattacharya, and E. Purdom Exon-level microarray analyses identify alternative splicing programs in breast cancer Mol Cancer Res 8 2010 961 974
49. J. Laudadio, M.W. Deininger, M.J. Mauro, B.J. Druker, and R.D. Press An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy J Mol Diagn 10 2008 177 180
50. C.V. Lefave, M. Squatrito, S. Vorlova, G.L. Rocco, C.W. Brennan, and E.C. Holland Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas EMBO J 30 2011 4084 4097
51. B. Lenhard, A. Sandelin, and P. Carninci Metazoan promoters: emerging characteristics and insights into transcriptional regulation Nat Rev Genet 13 2012 233 245
52. Z. Lian, A. Karpikov, J. Lian, M.C. Mahajan, S. Hartman, and M. Gerstein A genomic analysis of RNA polymerase II modification and chromatin architecture related to 3′ end RNA polyadenylation Genome Res 18 2008 1224 1237
53. H.G. Linhart, H. Lin, Y. Yamada, E. Moran, E.J. Steine, and S. Gokhale Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing Genes Dev 21 2007 3110 3122
54. I. Listerman, A.K. Sapra, and K.M. Neugebauer Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells Nat Struct Mol Biol 13 2006 815 822
55. H.W. Lo, H. Zhu, X. Cao, A. Aldrich, and F. Ali-Osman A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion Cancer Res 69 2009 6790 6798
56. S. Lois, N. Blanco, M. Martinez-Balbas, and X. de la Cruz The functional modulation of epigenetic regulators by alternative splicing BMC Genomics 8 2007 252
57. Y. Lu, H.P. Yao, and M.H. Wang Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets Cancer Lett 257 2007 157 164
58. L. Lum, and P.A. Beachy The Hedgehog response network: sensors, switches, and routers Science 304 2004 1755 1759
59. W. Ma, F. Giles, X. Zhang, X. Wang, Z. Zhang, and T.S. Lee Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors Int J Lab Hematol 33 2011 326 331
60. W. Ma, H. Kantarjian, X. Zhang, X. Wang, Z. Zhang, and C.H. Yeh JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms PLoS One 5 2010 e12165
61. E. Machackova, L. Foretova, M. Lukesova, P. Vasickova, M. Navratilova, and I. Coene Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer BMC Cancer 8 2008 140
62. P. Maggiora, S. Marchio, M.C. Stella, M. Giai, A. Belfiore, and M. De Bortoli Overexpression of the RON gene in human breast carcinoma Oncogene 16 1998 2927 2933
63. K.B. Marcu, S.A. Bossone, and A.J. Patel myc function and regulation Annu Rev Biochem 61 1992 809 860
64. J.A. Martin, and Z. Wang Next-generation transcriptome assembly Nat Rev Genet 12 2011 671 682
65. A.K. Maunakea, R.P. Nagarajan, M. Bilenky, T.J. Ballinger, C. D'Souza, and S.D. Fouse Conserved role of intragenic DNA methylation in regulating alternative promoters Nature 466 2010 253 257
66. F. Menghi, T.S. Jacques, M. Barenco, E.C. Schwalbe, S.C. Clifford, and M. Hubank Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development Cancer Res 71 2011 2045 2055
67. T. Miki, D.P. Bottaro, T.P. Fleming, C.L. Smith, W.H. Burgess, and A.M. Chan Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene Proc Natl Acad Sci U S A 89 1992 246 250
68. C.M. Misquitta-Ali, E. Cheng, D. O'Hanlon, N. Liu, C.J. McGlade, and M.S. Tsao Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer Mol Cell Biol 31 2011 138 150
69. C.S. Moller-Levet, G.N. Betts, A.L. Harris, J.J. Homer, C.M. West, and C.J. Miller Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis PLoS Comput Biol 5 2009 e1000571
70. M.A. Morgan, E. Magnusdottir, T.C. Kuo, C. Tunyaplin, J. Harper, and S.J. Arnold Blimp-1/Prdm1 alternative promoter usage during mouse development and plasma cell differentiation Mol Cell Biol 29 2009 5813 5827
71. C. Moyret-Lalle, C. Duriez, J. Van Kerckhove, C. Gilbert, Q. Wang, and A. Puisieux p53 induction prevents accumulation of aberrant transcripts in cancer cells Cancer Res 61 2001 486 488
72. T. Nakanishi, K.J. Bailey-Dell, B.A. Hassel, K. Shiozawa, D.M. Sullivan, and J. Turner Novel 5′ untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage Cancer Res 66 2006 5007 5011
73. G. Narla, A. DiFeo, Y. Fernandez, S. Dhanasekaran, F. Huang, and J. Sangodkar KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis J Clin Invest 118 2008 2711 2721
74. G. Narla, A. Difeo, H.L. Reeves, D.J. Schaid, J. Hirshfeld, and E. Hod A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk Cancer Res 65 2005 1213 1222
75. G. Narla, A. DiFeo, S. Yao, A. Banno, E. Hod, and H.L. Reeves Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread Cancer Res 65 2005 5761 5768
76. G. Narla, K.E. Heath, H.L. Reeves, D. Li, L.E. Giono, and A.C. Kimmelman KLF6, a candidate tumor suppressor gene mutated in prostate cancer Science 294 2001 2563 2566
77. K.P. Ng, A.M. Hillmer, C.T. Chuah, W.C. Juan, T.K. Ko, and A.S. Teo A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat Med 18 2012 521 528
78. D.G. Nowak, J. Woolard, E.M. Amin, O. Konopatskaya, M.A. Saleem, and A.J. Churchill Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors J Cell Sci 121 2008 3487 3495
79. K.R. Ostler, E.M. Davis, S.L. Payne, B.B. Gosalia, J. Exposito-Cespedes, and M.M. Le Beau Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins Oncogene 26 2007 5553 5563
80. G.P. Page, J.W. Edwards, G.L. Gadbury, P. Yelisetti, J. Wang, and P. Trivedi The PowerAtlas: a power and sample size atlas for microarray experimental design and research BMC Bioinformatics 7 2006 84
81. S. Pal, R. Gupta, H. Kim, P. Wickramasinghe, V. Baubet, and L.C. Showe Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development Genome Res 21 2011 1260 1272
82. Q. Pan, O. Shai, L.J. Lee, B.J. Frey, and B.J. Blencowe Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing Nat Genet 40 2008 1413 1415
83. A. Piekielko-Witkowska, H. Wiszomirska, A. Wojcicka, P. Poplawski, J. Boguslawska, and Z. Tanski Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors PLoS One 5 2010 e13690
84. G. Plotz, M. Casper, J. Raedle, I. Hinrichsen, V. Heckel, and A. Brieger MUTYH gene expression and alternative splicing in controls and polyposis patients Hum Mutat 33 2012 1067 1074
85. C. Pritchard, B. Mecham, R. Dumpit, I. Coleman, M. Bhattacharjee, and Q. Chen Conserved gene expression programs integrate mammalian prostate development and tumorigenesis Cancer Res 69 2009 1739 1747
86. R.O. Pritchard-Jones, D.B. Dunn, Y. Qiu, A.H. Varey, A. Orlando, and H. Rigby Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma Br J Cancer 97 2007 223 230
87. P. Pruunsild, A. Kazantseva, T. Aid, K. Palm, and T. Timmusk Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters Genomics 90 2007 397 406
88. P. Rajan, D.J. Elliott, C.N. Robson, and H.Y. Leung Alternative splicing and biological heterogeneity in prostate cancer Nat Rev Urol 6 2009 454 460
89. J. Rozowsky, A. Abyzov, J. Wang, P. Alves, D. Raha, and A. Harmanci AlleleSeq: analysis of allele-specific expression and binding in a network framework Mol Syst Biol 7 2011 522
90. V. Saint-Andre, E. Batsche, C. Rachez, and C. Muchardt Histone H3 lysine 9 trimethylation and HP1gamma favor inclusion of alternative exons Nat Struct Mol Biol 18 2011 337 344
91. E.M. Schaeffer, L. Marchionni, Z. Huang, B. Simons, A. Blackman, and W. Yu Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer Oncogene 27 2008 7180 7191
92. S. Schwartz, E. Meshorer, and G. Ast Chromatin organization marks exon-intron structure Nat Struct Mol Biol 16 2009 990 995
93. M.R. Schweiger, M. Kerick, B. Timmermann, and M. Isau The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations Cancer Metastasis Rev 30 2011 199 210
94. Z.H. Shah, S.U. Ahmed, J.R. Ford, S.J. Allison, J.R. Knight, and J. Milner A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes Mol Cell Biol 32 2012 704 716
95. T. Shimokawa, U. Tostar, M. Lauth, R. Palaniswamy, M. Kasper, and R. Toftgard Novel human glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal J Biol Chem 283 2008 14345 14354
96. S. Shukla, E. Kavak, M. Gregory, M. Imashimizu, B. Shutinoski, and M. Kashlev CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing Nature 479 2011 74 79
97. A. Sistayanarain, K. Tsuneyama, H. Zheng, H. Takahashi, K. Nomoto, and C. Cheng Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma Anticancer Res 26 2006 3585 3593
98. B. Sitohy, J.A. Nagy, and H.F. Dvorak Anti-VEGF/VEGFR therapy for cancer: reassessing the target Cancer Res 72 2012 1909 1914
99. N. Spies, C.B. Nielsen, R.A. Padgett, and C.B. Burge Biased chromatin signatures around polyadenylation sites and exons Mol Cell 36 2009 245 254
100. M. Sultan, M.H. Schulz, H. Richard, A. Magen, A. Klingenhoff, and M. Scherf A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome Science 321 2008 956 960
101. H. Sun, J. Wu, P. Wickramasinghe, S. Pal, R. Gupta, and A. Bhattacharyya Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq Nucleic Acids Res 39 2011 190 201
102. T. Takahashi, D. D'Amico, I. Chiba, D.L. Buchhagen, and J.D. Minna Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer J Clin Invest 86 1990 363 369
103. F. Talos, A. Abraham, A.V. Vaseva, L. Holembowski, S.E. Tsirka, and A. Scheel p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis Cell Death Differ 17 2011 1816 1829
104. C.G. Tepper, D.L. Boucher, P.E. Ryan, A.H. Ma, L. Xia, and L.F. Lee Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line Cancer Res 62 2002 6606 6614
105. B. Tian, J. Hu, H. Zhang, and C.S. Lutz A large-scale analysis of mRNA polyadenylation of human and mouse genes Nucleic Acids Res 33 2005 201 212
106. B. Tian, Z. Pan, and J.Y. Lee Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing Genome Res 17 2007 156 165
107. T. Timmusk, K. Palm, M. Metsis, T. Reintam, V. Paalme, and M. Saarma Multiple promoters direct tissue-specific expression of the rat BDNF gene Neuron 10 1993 475 489
108. R. Tomasini, K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, and C.C. Cheung TAp73 knockout shows genomic instability with infertility and tumor suppressor functions Genes Dev 22 2008 2677 2691
109. J.D. Turner, L.P. Pelascini, J.A. Macedo, and C.P. Muller Highly individual methylation patterns of alternative glucocorticoid receptor promoters suggest individualized epigenetic regulatory mechanisms Nucleic Acids Res 36 2008 7207 7218
110. E. Turpin, B. Dalle, A. de Roquancourt, L.F. Plassa, M. Marty, and A. Janin Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers Oncogene 18 1999 7834 7837
111. D. Ulveling, C. Francastel, and F. Hube When one is better than two: RNA with dual functions Biochimie 93 2011 633 644
112. B.O. Van Emburgh, and K.D. Robertson Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants Nucleic Acids Res 39 2011 4984 5002
113. A.H. Varey, E.S. Rennel, Y. Qiu, H.S. Bevan, R.M. Perrin, and S. Raffy VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy Br J Cancer 98 2008 1366 1379
114. J.P. Venables, R. Klinck, C. Koh, J. Gervais-Bird, A. Bramard, and L. Inkel Cancer-associated regulation of alternative splicing Nat Struct Mol Biol 16 2009 670 676
115. R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, and M.D. Wilkerson Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
116. G.S. Wang, and T.A. Cooper Splicing in disease: disruption of the splicing code and the decoding machinery Nat Rev Genet 8 2007 749 761
117. Z. Wang, M. Gerstein, and M. Snyder RNA-Seq: a revolutionary tool for transcriptomics Nat Rev Genet 10 2009 57 63
118. M.H. Wang, W.F. Lao, D. Wang, Y.L. Luo, and H.P. Yao Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain Cancer Biol Ther 6 2007 1121 1129
119. E.T. Wang, R. Sandberg, S. Luo, I. Khrebtukova, L. Zhang, and C. Mayr Alternative isoform regulation in human tissue transcriptomes Nature 456 2008 470 476
120. M.H. Wang, D. Wang, and Y.Q. Chen Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis 24 2003 1291 1300
121. L. Wang, J. Wang, S. Sun, M. Rodriguez, P. Yue, and S.J. Jang A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer Int J Oncol 29 2006 201 207
122. J. Winter, M. Kunath, S. Roepcke, S. Krause, R. Schneider, and S. Schweiger Alternative polyadenylation signals and promoters act in concert to control tissue-specific expression of the Opitz syndrome gene MID1 BMC Mol Biol 8 2007 105
123. D.W. Woessner, C.S. Lim, and M.W. Deininger Development of an effective therapy for chronic myelogenous leukemia Cancer J 17 2011 477 486
124. A. Yang, N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, and J. Bonnin p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours Nature 404 2000 99 103
125. K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata, and R. Yamamoto Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
126. L. Zhang, R. Bacares, S. Boyar, C. Hudis, K. Nafa, and K. Offit cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation Mutat Res 663 2009 84 89
127. L. Zhang, L. Chen, R. Bacares, J.M. Ruggeri, J. Somar, and Y. Kemel BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels Breast Cancer Res Treat 130 2011 1051 1056
128. Y.Q. Zhou, C. He, Y.Q. Chen, D. Wang, and M.H. Wang Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential Oncogene 22 2003 186 197
129. H.L. Zhou, M.N. Hinman, V.A. Barron, C. Geng, G. Zhou, and G. Luo Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner Proc Natl Acad Sci U S A 108 2011 E627 E635